| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-27 | 药明康德 | 603259 | 98.01 254.83 | 2.6 | 机构专用 | 發開手落在過程貨 | | Ka | 2月27日，药明康德大宗交易成交2.6万股，成交额254.83万元，占当日总成交额的0.11%，成交价98.01 元，较市场收盘价98.01元持平。 ...

智通财经2月27日讯（编辑 胡家荣）港股三大指数本月交易结束，全月整体震荡调整。恒生指数围绕27000点区间反复波动，恒生科技指数回调尤为显著， 月内累计跌幅超10%。 截至收盘，恒生指数累计下跌2.76%，报26630.54点；恒生科技指数累计下跌10.15%，报5137.84点；恒生国企指数累计下跌4.91%，报8859.49点。 值得关注的是，恒生科技指数本月创下2024年1月以来最大单月跌幅纪录。同期的恒生指数也领跌全球主要指数。 此轮调整，本质上反映出市场对当前估值水平与盈利预期的重新定价，投资者风险偏好趋于谨慎，整体资金配置策略更趋审慎。 机构称基本面修复支撑结构性机会 驱动逻辑切换：从业绩修复到政策催化 光大证券指出，当前港股处于"基本面温和修复、流动性内外共振、情绪中性偏暖"格局，市场正由资金驱动向业绩驱动切换，一季度结构性反弹可期。 布局三大主线：政策与季节性机会并重 中信证券指出，2025年四季度压制因素逐步消化，参考历史春季躁动规律，建议重点关注："十五五"政策主线(生物制造、具身智能、6G)；政策催化预期逆 转领域(外卖平台、地产)；春季躁动受益板块(非银金融)。 月度个股表现：景气赛 ...

| 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 广和通(00638) | 14.010 | 30.58 | 161.46% | 20.09% | | 国联民生(01456) | 5.020 | 9.85 | 135.06% | 14.43% | | 京城机电股份(00187) | 4.440 | 14.5 | 291.22% | 14.19% | | 东方证券(03958) | 6.170 | 10.13 | 96.60% | 13.22% | | 剑桥科技(06166) | 67.000 | 105.5 | 88.61% | 12.75% | | 康希诺生物(06185) | 35.480 | 72 | 143.07% | 11.24% | | 中州证券(01375) | 2.090 | 4.41 | 152.63% | 10.64% | | 中铝国际(02068) | 2.770 | 6.41 | 177.26% | 10.61% | | --- | --- | --- | --- | --- | | 龙旗科技(0 ...

随着近期多只生物医药股靓丽业绩放榜，今日港股创新药概念也集体活跃。其中，入选了2026年格隆 汇"下注中国"十大核心资产名单的药明合联涨超8%，领涨板块，药明生物涨超5%，康方生物、云顶新 耀、诺诚健华涨超4%，石药集团、再鼎医药、药明康德涨超3%。 | 代码 | 名称 | | 涨跌幅 V | 最新价 | 总市值 | 年初至今涨跌 | | --- | --- | --- | --- | --- | --- | --- | | 02268 | 药明合联 | 0 | 8.40% | 63.250 | 795.68亿 | 4.12% | | 02269 | 药明生物 | | 5.38% | 40.340 | 1669.08 Z | 28.31% | | 09926 | 康方生物 | | 4.81% | 106.800 | 983.78亿 | -5.49% | | 01952 | 云顶新耀 | | 4.27% | 37.600 | 132.95亿 | 1.68% | | 69660 | 诺成健华 | | 4.04% | 12.090 | 213.04亿 | -1.71% | | 01093 | 石约集团 | | 3. ...

Group 1 - CXO concept stocks have shown significant gains, with WuXi AppTec (02268) rising by 7.97% to HKD 63, WuXi Biologics (02269) increasing by 4.7% to HKD 40.08, WuXi PharmaTech (603259) (02359) up by 2.28% to HKD 19.7, and Kanglong Chemical (300759) (03759) also up by 2.28% to HKD 19.7 [1] - According to a report from Citi, investor focus is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to internal AI adoption by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report highlights that leading companies in the industry may experience overselling during this market window lacking catalysts, creating attractive entry points for investors with a 3 to 12-month investment horizon [1]

每经AI快讯，2月27日，港股CXO概念股涨幅居前，药明合联(02268.HK)涨7.97%，报63港元；药明生 物(02269.HK)涨4.7%，报40.08港元；药明康德(02359.HK)涨2.28%，报19.7港元；康龙化成(03759.HK) 涨2.28%，报19.7港元。 ...

Group 1 - The core viewpoint of the article highlights the recent performance of CXO concept stocks, with notable gains in companies such as WuXi AppTec (02268) up 7.97% to HKD 63, WuXi Biologics (02269) up 4.7% to HKD 40.08, WuXi PharmaTech (02359) up 2.28% to HKD 19.7, and Kanglong Chemical (03759) also up 2.28% to HKD 19.7 [1] - According to a report from Citi, the focus of investors is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to the accelerated adoption of AI by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report emphasizes that leading companies in the industry may experience overselling during this market window lacking catalysts, creating more attractive entry points for investors with a 3 to 12-month investment horizon [1]

Group 1: Market Overview - The Hang Seng Index opened high but closed down 384 points, or 1.44%, at 26,381 points, with significant selling pressure observed throughout the day [3][4] - The market saw a total turnover of 25.93 billion HKD, with net outflow from northbound trading amounting to 736.6 million HKD [3] Group 2: Company Performance - NIO's subsidiary GeniTech secured over 2.257 billion RMB in investment from Chinese investors, maintaining a 62.7% controlling stake post-transaction [12] - New World Department Store China reported a 3.93 times increase in interim profit to 15.327 million HKD, despite a 12.44% decrease in revenue to 536 million HKD [13] - Chow Tai Fook Jewelry Group announced a 15.26% increase in interim profit to 1.334 billion HKD, with revenue rising 5.9% to 12.827 billion HKD [14] - Baidu reported a 65.68% decrease in net profit to 1.782 billion RMB for the fourth quarter, with total revenue declining 4.06% to 32.74 billion RMB [15] Group 3: Industry Developments - Hong Kong Exchanges and Clearing is exploring the development of a multi-asset tokenization platform, contingent on technological capabilities and market demand [7] - The People's Bank of China issued a notice to enhance the management of RMB cross-border interbank financing, aiming to improve transparency and stability in offshore RMB liquidity [10] - The Hong Kong government plans to inject 10 billion HKD into the Hong Kong-Shenzhen Innovation and Technology Park and the New Territories Science Park to bolster public-private partnerships [9]

来源：格隆汇APP 格隆汇2月27日｜港股主要指数午后拉升，其中，恒生指数涨超1%，恒生科技指数涨近1%，国企指数 涨0.74%。恒生指数成分股中，新鸿基地产涨超6%领涨，药明生物涨超4%，石药集团、药明康德涨超 3%，网易、携程、腾讯、泡泡玛特、蒙牛乳业、中通快递涨超2%。 | 代码 | 名称 | | 涨跌幅 √ | 年初至今涨跌 | 总市值 | | --- | --- | --- | --- | --- | --- | | 00016 | 新鸿基地产 | (0) | 6.02% | 52.59% | 4187.29 Z | | 02269 | 药明生物 | | 4.81% | 27.61% | 1659.98亿 | | 01093 | 石药集团 | | 3.67% | 17.32% | 1139.57亿 | | 02359 | 药明康德 | | 3.04% | 20.36% | 3544.7 Z | | 099999 | 网易-S | | 2.74% | -16.22% | 5692.45 Z | | 09961 | 携程集团-S | | 2.60% | -25.85% | 2685亿 | | 00700 ...

消息面上，国家药监局发布2025年度创新医疗器械等产品注册审批情况，2025年，国家药监局按照《创 新医疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作，共收到创新医疗 器械特别审批申请457项，其中104项获准进入创新医疗器械特别审查程序；收到优先申请38项，其中26 项获准优先审批。 华福证券指出，考虑到医药已调整半年，很充分，继续坚定医药科技主线，26年全年策略如下：1）创 新药：主要三个方向：1、收入和业绩兑现；2、超预期BD兑现的标的；3、前沿技术平台如分子胶、小 核酸、通用/体内CART、基因治疗等弹性主题；2）医疗器械：设备看补库和招投标，如手术机器人和 内镜等，耗材看集采受益的创新耗材如神经介入、外周介入和电生理等方向；3）寻找变化标的：考虑 到中央经济工作会议明确提到26年坚持内需主导，建设强大国内市场，期待内需消费崛起，医药内需相 关公司或将迎来拐点。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药 ...